-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BOLD-100 in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BOLD-100 in Colorectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BOLD-100 in Colorectal Cancer Drug Details: BOLD-100 (IT-139, NKP-1339) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BOLD-100 in Colon Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BOLD-100 in Colon Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BOLD-100 in Colon Cancer Drug Details: BOLD-100 (IT-139, NKP-1339) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BOLD-100 in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BOLD-100 in Pancreatic Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BOLD-100 in Pancreatic Cancer Drug Details: BOLD-100 (IT-139, NKP-1339) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BOLD-100 in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BOLD-100 in Gastric Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BOLD-100 in Gastric Cancer Drug Details: BOLD-100 (IT-139, NKP-1339) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BOLD-100 in Gastrointestinal Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BOLD-100 in Gastrointestinal Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BOLD-100 in Gastrointestinal Tumor Drug Details: BOLD-100 (IT-139, NKP-1339) is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – BOLD-100 in Bile Duct Cancer (Cholangiocarcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BOLD-100 in Bile Duct Cancer (Cholangiocarcinoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BOLD-100 in Bile Duct Cancer (Cholangiocarcinoma) Drug Details: BOLD-100 (IT-139,...
-
Analyst Opinions
Decarbonizing Maritime and Aviation Overview by Key Energy Transition Technologies and Case Studies, 2024 Update
Decarbonizing Maritime and Aviation Market Report Overview The automotive sector experiences a strong growth in demand for electric vehicles. However, the aviation and maritime sectors have been slow to decarbonize. To incentivize emission reductions, both sectors have set bold net-zero targets. However, according to the IEA, the sectors remain disoriented. Demand for cost-competitive and energy-dense fuels has led aviation and maritime to represent two of the most difficult to abate sectors. Both sectors will likely need to engage with a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BOLD-100 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BOLD-100 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BOLD-100 in Solid Tumor Drug Details: BOLD-100 (IT-139, NKP-1339) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BOLD-100 in Metastatic Pancreatic Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BOLD-100 in Metastatic Pancreatic Cancer Drug Details: BOLD-100 (IT-139, NKP-1339) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BOLD-100 in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BOLD-100 in Metastatic Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BOLD-100 in Metastatic Colorectal Cancer Drug Details: BOLD-100 (IT-139, NKP-1339)...